Browse the evidence

Long-term vitamin D supplementation does not reduce the risk of major adverse cardiovascular events (MACE), myocardial infarction, stroke, or all-cause mortality compared to placebo.

Based on this large meta-analysis, taking vitamin D supplements will not protect you from heart attacks, strokes, or early death, even if you have low levels. It is not indicated for cardiovascular prevention.

Advanced maternal age (≥35 years) is a strong, non-modifiable risk factor for GDM, with risk increasing linearly with age.

If you are over 35, be aware your risk for GDM is higher. Prioritize the lifestyle interventions (diet and exercise) mentioned earlier, as they are even more critical for this age group.

Skeletal muscle contains a novel FBN1+ fibro-adipogenic progenitor (FAP) subtype in humans, which is also present in mice and may contribute to heterotopic ossification.

This is a basic science finding. The FBN1+ FAP subtype may play a role in bone formation within muscle (heterotopic ossification) after injury.

Tirzepatide treatment does not increase the risk of major adverse cardiovascular events (MACE-4) in patients with type 2 diabetes compared to control groups.

If you have type 2 diabetes, taking tirzepatide once a week does not increase your risk of heart attacks, strokes, or cardiovascular death compared to other standard treatments. This holds true for patients with both low and high existing heart risk, providing a safe option for cardiovascular protection while managing blood sugar.

High-dose vitamin D supplementation (4000-10,000 IU/day) does not improve bone health and is associated with a significant decrease in volumetric bone mineral density (BMD) at the radius and tibia compared to a low dose (400 IU/day).

If you are a healthy adult over 55 with normal vitamin D levels, taking high-dose vitamin D (4000-10,000 IU daily) will not strengthen your bones and may actually weaken them over time. Stick to standard recommended doses (around 400-800 IU) unless you have a diagnosed deficiency, as high doses can disrupt the hormones that regulate bone density.

NCL-1 (TRIM2/Brat) mediates lifespan extension in major longevity pathways by limiting nucleolar size and reducing fibrillarin expression.

In C. elegans, the protein NCL-1 is essential for the lifespan benefits of various longevity pathways. It works by reducing the size of the nucleolus and lowering fibrillarin levels. This suggests that regulating nucleolar function is a critical step in extending life in these genetic models.

GrimAge version 2 (GrimAge2), an epigenetic clock based on DNA methylation, is a superior predictor of all-cause mortality and age-related morbidity compared to the original GrimAge and other epigenetic clocks.

GrimAge2 is a blood test that measures your biological age based on DNA methylation patterns. It is a more accurate predictor of your risk for death and age-related diseases (like heart disease and diabetes) than your actual age or other aging clocks. While you cannot change your chronological age, your biological age can be influenced by lifestyle factors such as smoking, diet, and physical activity. Monitoring this metric can provide early warning signs of health decline, allowing for proactive lifestyle interventions.

Leptin signaling in POMC neurons is essential for energy homeostasis, and leptin deficiency causes obesity, which can be corrected by leptin administration.

Leptin is crucial for weight regulation, but it only works as a treatment for those with a specific genetic deficiency. It is not a general weight-loss drug for the majority of people with obesity.

Exogenous leptin therapy is effective in treating obesity and metabolic disorders only in individuals with congenital leptin deficiency or generalized lipodystrophy, but is ineffective for the majority of people with common obesity.

Leptin therapy is not a weight-loss drug for the general public. It is a life-saving treatment for rare genetic conditions where the body produces no leptin. For most people with obesity, adding more leptin does not work because the body has stopped listening to it.

Dual-PPARα/γ agonists (glitazars) like muraglitazar, tesaglitazar, and aleglitazar have largely failed in clinical development for type 2 diabetes and cardiovascular disease due to severe safety concerns, including heart failure, renal dysfunction, and increased mortality.

Do not seek out dual-PPAR agonists like muraglitazar or aleglitazar. These drugs were developed for diabetes and heart health but were withdrawn from the market because they caused serious side effects like heart failure and kidney problems. Stick to established treatments with proven safety profiles.

Classically activated (M1) macrophages reprogram their metabolism to favor aerobic glycolysis and lactate production over oxidative phosphorylation, leading to TCA cycle interruptions and accumulation of metabolites like citrate and succinate.

When immune cells fight acute threats, they switch to a fast, inefficient energy mode (glycolysis) that produces lactate and specific metabolites. This metabolic shift is a key part of the inflammatory response.

NOS1-expressing glutamatergic neurons in the preoptic area link thermal sensory information to NREM onset and body cooling.

This is a basic science finding explaining how warmth triggers sleep at the neural level. It confirms that sleep initiation is an active process driven by specific brain circuits responding to warmth, rather than a passive state.

Sarcopenia should not be the sole criterion for declining or de-listing candidates for liver transplantation; it should be considered in the full context of other medical and psychosocial factors.

If you have sarcopenia, it does not automatically disqualify you from a liver transplant. It is a risk factor that your medical team will consider alongside your overall health. It may motivate your team to prioritize your case or consider different types of donor livers.

Atherogenesis is fundamentally driven by the accumulation of oxidatively modified LDL in the arterial intima, facilitated by endothelial dysfunction and scavenger receptor uptake by macrophages to form foam cells.

High LDL cholesterol is a primary cause of atherosclerosis. The risk is highest when LDL is oxidized and taken up by macrophages to form foam cells. Managing LDL levels and reducing oxidative stress are key to preventing plaque buildup.

There is no significant sex difference in the relative risk of cancer mortality associated with diabetes; the risk increase is comparable for both men and women.

While diabetes increases your risk of cancer, this relative increase is similar for both men and women. Focus on standard cancer screening and healthy lifestyle habits rather than worrying about a sex-specific cancer risk amplification from diabetes.

Self-reported sleep quality is NOT associated with neural health (white matter integrity) in healthy adults, despite associations in clinical populations.

Don't panic about occasional poor sleep causing permanent brain damage. This study found no link between self-reported sleep quality and white matter integrity in healthy adults. While clinical sleep disorders are serious, healthy sleep variations do not appear to harm brain structure.

Inhibition of IL-11 signaling through genetic deletion or therapeutic antibody administration extends mammalian healthspan and lifespan by mitigating age-associated metabolic decline, frailty, and tissue fibrosis.

This research suggests that targeting the IL-11 pathway could be a viable strategy for extending healthspan and lifespan in humans. While the study was conducted in mice, the findings support the potential of anti-IL-11 therapies, which are already in clinical trials for other conditions, to mitigate age-related decline. For now, this remains a preclinical finding, but it highlights IL-11 as a promising target for future longevity interventions.

LEAP2 acts as a GHSR antagonist that hyperpolarizes arcuate NPY neurons and prevents acyl-ghrelin from activating them, thereby blunting ghrelin's orexigenic effects.

This is a deep biological mechanism showing how your brain processes hunger signals. LEAP2 physically blocks the hunger signal at the neuronal level. This explains why high levels of LEAP2 in obesity might contribute to 'ghrelin resistance,' where the hunger signal is less effective.

DNA methylation patterns (epigenetic clocks) are among the best-studied and most accurate molecular biomarkers for predicting chronological age.

DNA methylation tests (epigenetic clocks) are currently the most reliable molecular tool for estimating your biological age, with some tests achieving an error margin of less than 5 years.

Long-term exercise training does not significantly reduce the risk of mortality or hospitalization in older adults.

For older adults, engaging in moderate-intensity multicomponent exercise 2-3 times per week for at least a year does not significantly reduce the risk of mortality or hospitalization. However, it does significantly reduce the risk of falls.

VLCKD is contraindicated in patients with Type 1 Diabetes, renal failure, liver failure, and certain cardiac conditions due to risks of euglycemic ketoacidosis, electrolyte imbalance, and metabolic stress.

Do not attempt this diet if you have Type 1 Diabetes, kidney or liver disease, or severe heart failure. These conditions make the metabolic shift of ketosis dangerous. Consult your doctor for safer alternatives.

Multi-omics approaches (proteomics, transcriptomics) are necessary to accurately measure and understand the complexity of inflammaging, as single biomarkers like IL-6 or TNF-α are insufficient.

Current single-marker tests for inflammation are limited. Multi-omics approaches offer a more comprehensive view of inflammaging, which may lead to better diagnostics and targeted therapies in the future.

Lorcaserin was withdrawn from the US market in 2020 due to an increased risk of cancer observed in clinical trials, despite showing modest weight loss efficacy.

Lorcaserin (Belviq) is no longer available in the US because it was linked to a higher risk of cancer. Do not seek this medication.

Genetic testing for exercise prescription (e.g., predicting 'power' vs 'endurance' response) lacks sufficient scientific evidence and is not currently supported as a scientifically-sound approach.

Do not rely on commercial genetic tests to dictate your training program (e.g., whether you should do more strength or cardio work). The science does not currently support using DNA to prescribe specific training protocols. Focus on proven training principles and monitor your actual response to training.